What’s Causing the Decline in Clearside Biomedical Stock (CLSD) Today?

Written by Emily J. Thompson, Senior Investment Analyst

Source: TipRanks

Updated: Nov 24 2025

0mins

Source: TipRanks

Bankruptcy Filing: Clearside Biomedical (CLSD) announced its voluntary Chapter 11 bankruptcy filing, following a thorough evaluation of strategic options by its Board of Directors.
Asset Sale Plans: The company plans to sell all or part of its assets during the bankruptcy process, inviting binding offers that would be free of liens and interests, while seeking court permission to continue normal operations.
Stock Performance: Following the bankruptcy announcement, CLSD stock dropped 70.59% in pre-market trading, marking an 80.91% decline year-to-date and an 83.21% decrease over the past year.
Analyst Consensus: The current consensus rating for Clearside Biomedical is Hold, based on a single Hold rating, with no price target set, which may change as analysts reassess the situation post-bankruptcy news.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free